Conditions: Metastatic Colorectal Cancer
Keywords: Oncology Cancer metastatic colorectal cancer EGFr Panitumumab Clinical Trail Amgen
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1183
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the treatment effect of panitumumab in combination with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer

Detailed description:

Arms:
arm 1: Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity. arm 2: Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.

Interventions: intervention 1: Panitumumab intervention 2: FOLFOX regimen
Intervention descriptions: intervention 1: Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy. intervention 2: The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.

Protocol document: